Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 6Terminated 5Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Non-Hodgkin 12Lymphoma 12Recurrence 11Multiple Myeloma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Leukemia 9Leukemia, Biphenotypic, Acute 8Ovarian Neoplasms 7Neoplasms 7Lymphoma, Mantle-Cell 7Myeloproliferative Disorders 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell 6Hodgkin Disease 6Hematologic Neoplasms 6Lymphoma, Follicular 5Immunoproliferative Disorders 5Immune System Diseases 5Lymphoproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Lymphatic Diseases 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Mesothelioma 3Lung Neoplasms 3

Interventions

Carboplatin 25Paclitaxel 24pembrolizumab 22Cyclophosphamide 14Gemcitabine 10Capecitabine 10Doxorubicin 9Specimen Handling 8Nivolumab 8Taxes 7Magnetic Resonance Spectroscopy 7sacituzumab govitecan 6olaparib 6Cisplatin 6eribulin 5durvalumab 5atezolizumab 5Radiotherapy 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5capivasertib 4Epirubicin 4Docetaxel 4Biopsy 4niraparib 3Vinorelbine 3Radiation 3Fulvestrant 3Blood Specimen Collection 3trastuzumab deruxtecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Triple Negative Breast Neoplasms × fludarabine × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡